Literature DB >> 12578791

Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma.

Chi-Chao Chan1, DeFen Shen, Joseph J Hackett, Ronald R Buggage, Nadine Tuaillon.   

Abstract

OBJECTIVE: Chemokines have a range of biologic activities, including regulation of leukocyte trafficking, modulation of hematopoietic cell proliferation, and adhesion to extracellular matrix molecules. Specifically, B-lymphocyte chemoattractant (BLC); BCA-1; CXCL13, SCYB13) and stromal cell-derived factor-1 (SDF-1, CXCL12, SCYB12) are chemotactic for human B cells, and their ligands CXCR4 and CXCR5 are differentially expressed on B cells, including malignant B cells. We investigated the expression of these chemokine/chemokine receptors in eyes with primary intraocular B-cell lymphoma (PIOL).
DESIGN: Observational case series (human tissue study).
METHODS: Three freshly enucleated eyes with PIOL and a normal autopsied eye were frozen and sectioned. The sections were evaluated using immunohistochemistry (avidin-biotin-complex immunoperoxidase technique) for CXCR4, CXCR5, BLC, and SDF-1 to detect the expression and location. Reverse transcriptase-polymerase chain reaction was used to detect chemokine transcripts of CXCR4, CXCR5, BLC, and SDF-1 in PIOL and retinal pigment epithelium (RPE) cells after microdissection-either by laser capture (Arcturus) or by manual dissection-from frozen sections. MAIN OUTCOME MEASURES AND
RESULTS: The three PIOL eyes showed similar pathology, with typical diffuse large B-lymphoma cells subjacent to the RPE. The eyes also demonstrated a similar chemokine profile. High expression levels of CXCR4 and CXCR5 were found limited to the lymphoma cells. In contrast, BLC protein was expressed in the RPE but not located in other ocular resident cells. SDF-1 was barely detected in a few RPE cells. CXCR4 and CXCR5 transcripts were detected abundantly in lymphoma cells, whereas BLC and SDF-1 transcripts were detected only in the RPE and not the malignant cells. No chemokine expression was detected on the RPE cells in the normal control eye.
CONCLUSIONS: Chemokines and chemokine receptors selective for B cells were identified in RPE and malignant B cells, respectively. BLC, and possibly SDF-1, attracts both normal and malignant B-cells while promoting migration of only small numbers of T cells and macrophages. We propose that B-cell chemokines may be involved in the pathogenesis of PIOL by selectively attracting lymphoma cells to the RPE from the choroidal circulation. Our data suggest that inhibition of B-cell chemoattractants could be a future strategy for the treatment of PIOL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578791     DOI: 10.1016/S0161-6420(02)01737-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  35 in total

Review 1.  Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.

Authors:  Chi-Chao Chan; James L Rubenstein; Sarah E Coupland; Janet L Davis; J William Harbour; Patrick B Johnston; Nathalie Cassoux; Valerie Touitou; Justine R Smith; Tracy T Batchelor; Jose S Pulido
Journal:  Oncologist       Date:  2011-11-01

Review 2.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 3.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

Review 4.  Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma.

Authors:  Chi-Chao Chan; H Nida Sen
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

5.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

6.  Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.

Authors:  Zhuqing Li; Sankaranarayana P Mahesh; De Fen Shen; Baoying Liu; Willie O Siu; Frank S Hwang; Qing-Chen Wang; Chi-Chao Chan; Ira Pastan; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

7.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

8.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

Review 9.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

10.  CXCL13 Signaling in the Tumor Microenvironment.

Authors:  Muzammal Hussain; Jinsong Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.